4//SEC Filing
Costantino John R 4
Accession 0001209191-06-067073
CIK 0001351197other
Filed
Dec 26, 7:00 PM ET
Accepted
Dec 27, 3:40 PM ET
Size
16.6 KB
Accession
0001209191-06-067073
Insider Transaction Report
Form 4
Costantino John R
Director
Transactions
- Conversion
Series E Convertible Preferred Stock
2006-12-26−197,458→ 0 total(indirect: By NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG)→ Common Stock (197,458 underlying) - Purchase
Common Stock
2006-12-26$6.00/sh+174,833$1,048,998→ 372,291 total(indirect: By NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG) - Conversion
Common Stock
2006-12-26+273,129→ 273,129 total(indirect: By NGN Biomed Opportunity I, L.P.) - Purchase
Common Stock
2006-12-26$6.00/sh+241,833$1,450,998→ 514,962 total(indirect: By NGN Biomed Opportunity I, L.P.) - Conversion
Series E Convertible Preferred Stock
2006-12-26−273,129→ 0 total(indirect: By NGN Biomed Opportunity I, L.P.)→ Common Stock (273,129 underlying) - Conversion
Common Stock
2006-12-26+197,458→ 197,458 total(indirect: By NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG)
Footnotes (5)
- [F1]Immediately following the closing of the initial public offering of the Issuer?s Common Stock all outstanding shares of Preferred Stock will be automatically converted, for no additional consideration, into shares of the Issuer's Common Stock.
- [F2]Mr. Costantino is the Managing General Partner of NGN Capital LLC. NGN Capital LLC is the managing limited partner of NGN BioMed Opportunity I, GmbH & Co. Beteiligungs KG and the sole general partner of NGN BioMed I, GP, L.P, the sole general partner of NGN BioMed Opportunity I, L.P. Mr. Costantino disclaims beneficial ownership of the securities held directly by NGN BioMed Opportunity I, GmbH & Co. Beteiligungs KG, NGN BioMed Opportunity I, L.P. and NGN Capital LLC except to the extent of any indirect pecuniary interest in his distributive share therein.
- [F3]Represents total amount of common stock owned directly by NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG.
- [F4]Represents total amount of common stock owned directly by NGN BioMed Opportunity I, L.P.
- [F5]Reflects a 1 for 4.25 reverse stock split, effected on December 19, 2006, pursuant to which each share of Series E Convertible Preferred Stock became convertible into approximately 0.235 of a share of common stock.
Documents
Issuer
ARTES MEDICAL INC
CIK 0001351197
Entity typeother
Related Parties
1- filerCIK 0001383128
Filing Metadata
- Form type
- 4
- Filed
- Dec 26, 7:00 PM ET
- Accepted
- Dec 27, 3:40 PM ET
- Size
- 16.6 KB